nofazinlimab,lenvatinib
eisai pharmaceutical,eqrx,cstone pharmaceuticals
['hcc', 'nofazinlimab', 'lenva']
csstone presents updated results of anti-pd-1 antibody nofazinlimab in combination with lenvatinib as first-line therapy in patients with non-resectable hepatocellular carcinoma (hcc) at asco 2022 | antibodies 